Choline Salicylate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Choline Salicylate: From Inflammatory Pain to Prinzmetal Angina
One-Sentence Summary
Choline salicylate is a non-acetylated salicylate with anti-inflammatory and analgesic properties, historically used for musculoskeletal pain and inflammatory conditions. The TxGNN model predicts it may be effective for Prinzmetal Angina, achieving a prediction score of 99.84%; however, this indication currently has no supporting clinical trials or published literature, placing it at the lowest evidence tier (L5). Notably, the second-ranked prediction — rheumatoid arthritis — carries L3-level observational evidence from documented clinical use in the 1970s–1980s and warrants separate consideration as a more actionable repurposing candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anti-inflammatory and analgesic use (non-acetylated salicylate class; no Singapore registration on record) |
| Predicted New Indication | Prinzmetal Angina |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 — Model prediction only; no clinical studies found |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for choline salicylate in this dataset. Based on known pharmacological properties, choline salicylate is a non-acetylated salicylate that inhibits cyclooxygenase (COX-1 and COX-2) in a reversible manner, thereby reducing prostaglandin and thromboxane A₂ (TXA₂) synthesis. Unlike aspirin, the non-acetylated structure results in weaker and reversible platelet COX-1 inhibition, which theoretically translates to a more favourable gastrointestinal safety profile for long-term use.
The TxGNN model may be inferring a mechanistic link through the COX-1 → TXA₂ → platelet-mediated vasoconstriction pathway: theoretically, reducing TXA₂ synthesis could attenuate platelet-driven coronary spasm. Prinzmetal angina (variant angina), however, is primarily characterised by episodic rest-onset chest pain caused by transient coronary artery vasospasm driven by smooth muscle hyperreactivity and endothelial dysfunction — conditions managed with calcium channel blockers and long-acting nitrates, not anti-inflammatory or antiplatelet agents.
In practice, aspirin — a closely related and more potent COX-1 inhibitor — has not demonstrated clear benefit in Prinzmetal angina and may even exacerbate vasospasm in certain cases by suppressing prostacyclin (PGI₂) production. Extrapolating this concern to choline salicylate, which has weaker COX-1 inhibitory activity, makes clinical translation even less plausible. The high TxGNN score likely reflects a graph-based structural/network similarity pattern rather than a mechanistically validated pathway, and the prediction must be treated as hypothesis-generating only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Choline salicylate (DB14006) is currently not registered or marketed in Singapore. No product licences are on record with the Health Sciences Authority (HSA).
Safety Considerations
Please refer to the package insert for safety information.
Note for prescribers: As a salicylate-class compound, choline salicylate shares class-level concerns common to NSAIDs — including potential renal prostaglandin suppression, gastrointestinal effects, and interactions with anticoagulants — though non-acetylated salicylates are generally considered to have a more favourable GI and platelet safety profile than aspirin. Formal contraindication and warning data specific to this compound were not available in the current evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model assigns a high prediction score (99.84%) to choline salicylate for Prinzmetal angina, but this is unsupported by any clinical trials or published literature; the pathophysiological rationale is speculative, and the known mechanism of the salicylate class in coronary physiology raises the possibility of net harm rather than benefit in this indication.
To proceed, the following is needed:
- MOA data: Retrieve full mechanism of action and pharmacology from DrugBank (DB14006) to confirm or refute the TXA₂-vasospasm hypothesis
- Safety package: Download and parse the TFDA package insert PDF to populate key warnings and contraindications (currently a blocking data gap)
- Preclinical evidence review: Conduct a systematic search for salicylate class effects on coronary vasospasm in animal and in vitro models
- Priority redirect — Rheumatoid Arthritis (Rank 2, L3): The second-ranked TxGNN prediction for rheumatoid arthritis has 4 supporting observational publications and a documented history of clinical use in the 1970s–1980s. This represents a significantly more viable near-term repurposing candidate. A focused safety review, updated literature search for modern RA studies, and assessment of current standard-of-care relevance should be prioritised over the Prinzmetal angina hypothesis.
- Market feasibility: Since the drug has no Singapore registration, a regulatory pathway assessment would be required before any clinical development could proceed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.